This Article  • Full text  • PDF  • CME Course for This Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neoplasms  • Alert me on articles by topic

A Population-Based Study of Clinical Practices in France

Florent Grange, MD, PhD; Fabien Vitry, MD; Florence Granel-Brocard, MD; Dan Lipsker, MD, PhD; Francois Aubin, MD, PhD; Guy Hédelin, PhD; Sophie Dalac, MD; François Truchetet, MD; Catherine Michel, MD; Marie-Laure Batard, MD; Béatrice Baury, PhD; Jean-Michel Halna, MD; Jean Luc Schmutz, MD; Christian Delvincourt, MD; Georges Reuter, MD; Stéphane Dalle, MD; Phillipe Bernard, MD, PhD; Arlette Danzon, MD

Arch Dermatol. 2008;144(5):629-636.

Objective  To describe current management of cutaneous melanoma (CM) and identify factors accounting for disparities.

Design  Retrospective population-based study using survey of cancer registries and pathology laboratories, and questionnaires to physicians.

Setting  Five regions covering 19.2% of the French territory and including 8.2 million inhabitants.

Patients  Incident cases of patients with stage I to stage II (hereinafter, stage I-II) tumors staged according to the American Joint Committee on Cancer Staging guidelines and nodal stage III CM in 2004.

Main Outcome Measures  Modalities of diagnosis and excision, surgical margins, sentinel lymph node biopsy, adjuvant therapies and surveillance procedures, and their variations according to age, sex, residence, location of primary CM, Breslow thickness, type of physicians, modalities of decisions, and health care patterns.

Results  Clinical stage I-II CMs (n = 710 cases) slightly predominated in females (53%), with a lower mean Breslow thickness (1.4 mm) than in males (1.9 mm). Initial excisions were most often performed by private dermatologists and wide excisions by surgeons. Narrow margins (8%) were associated with advanced age, higher Breslow thickness, and head location. Sentinel lymph node biopsy was performed in 34% of CMs thicker than 1.0 mm, depending on geographical regions, distance from reference centers, and health care patterns. Adjuvant therapies (mainly low-dose interferon) were proposed in 53% of thick CMs (>1.5 mm), depending on the patient's age and geographical region. In contrast with French recommendations, surveillance procedures frequently included systematic medical imaging. Stage III nodal CMs (n = 89 cases) predominated in males (62%). After lymphadenectomy, adjuvant therapies (including high-dose interferon in 32% of cases and chemotherapies in 24% of cases) were proposed in 68% of cases, depending on the patient's age and geographical region. A complete 1-year high-dose interferon regimen was administered in less than 10% of cases.

Conclusion  Large disparities still exist in the management of CM in France, depending to a greater extent on medical and geographical environment than on the characteristics of either patients or tumors.

Author Affiliations: Service de Dermatologie, Hôpital Robert Debré, Reims, France (Drs Grange and Bernard); Unité d’Aide Méthodologique à la Recherche Clinique, Hôpital Maison Blanche, Reims (Drs Vitry and Baury); Service de Dermatologie, Hôpital Fournier, Nancy, France (Drs Granel-Brocard and Schmutz); Clinique Dermatologique, Hôpital Civil, Strasbourg, France (Dr Lipsker); Service de Dermatologie, Hôpital Saint Jacques, Besançon, France (Dr Aubin); Registre des Cancers du Bas-Rhin, Strasbourg (Drs Hédelin and Halna); Réseau Français des Registres de Cancers FRANCIM (Drs Hédelin, Halna, and Danzon); Service de Dermatologie, Hôpital du Bocage, Dijon, France (Dr Dalac); Service de Dermatologie, Hôpital Beauregard, Thionville, France (Dr Truchetet); Service de Dermatologie, Hôpital du Moenschberg, Mulhouse, France (Dr Michel); Service de Dermatologie, Hôpital Louis Pasteur, Colmar, France (Dr Batard); Cabinet de Dermatologie, Château-Thierry, France (Dr Delvincourt); Cabinet de Dermatologie, Strasbourg (Dr Reuter); Service de Dermatologie, Hôpital de l'Hôtel-Dieu, Lyon, France (Dr Dalle); and Registre des tumeurs du Doubs, CHU de Besançon, Besançon, France (Dr Danzon).

RELATED ARTICLES

This Month in Archives of Dermatology
Arch Dermatol. 2008;144(5):580.
FULL TEXT  

How Melanoma Is Treated in Real Life
Reinhard Dummer and Dirk Schadendorf
Arch Dermatol. 2008;144(5):664-665.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How Melanoma Is Treated in Real Life
Dummer and Schadendorf
Arch Dermatol 2008;144:664-665.
FULL TEXT